By Berlanga H.B. No. 2571 75R7055 JMM-F A BILL TO BE ENTITLED 1-1 AN ACT 1-2 relating to the substitution of certain drugs by a pharmacist. 1-3 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: 1-4 SECTION 1. Section 40(l), Texas Pharmacy Act (Article 1-5 4542a-1, Vernon's Texas Civil Statutes), is amended to read as 1-6 follows: 1-7 (l) Drug product selection as authorized in this section 1-8 shall not apply to enteric-coated tablets; controlled release 1-9 products; injectable suspensions, other than antibiotics; 1-10 suppositories containing active ingredients for which systemic 1-11 absorption is necessary for therapeutic activity; narrow 1-12 therapeutic index drugs; and different delivery systems for 1-13 aerosol or nebulizer drugs. This subsection shall not apply to 1-14 any drug product which is determined to be generically equivalent 1-15 to the brand prescribed, except for narrow therapeutic index drugs. 1-16 The interchange of narrow therapeutic index drugs requires 1-17 specific written authorization by the prescribing physician. In 1-18 this subsection, "narrow therapeutic index drugs" means medications 1-19 defined by the federal Food and Drug Administration as having a 1-20 narrow therapeutic index, including digoxin, phenytoin, warfarin 1-21 sodium, theophylline, levothryroxine, carbamazine, valproic acid, 1-22 and lithium. 1-23 SECTION 2. This Act takes effect September 1, 1997. 1-24 SECTION 3. The importance of this legislation and the 2-1 crowded condition of the calendars in both houses create an 2-2 emergency and an imperative public necessity that the 2-3 constitutional rule requiring bills to be read on three several 2-4 days in each house be suspended, and this rule is hereby suspended.